AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8931413
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 750 mg t.i.d. and metronidazole 500 mg t.i.d. for 14 days (group III)
Trial: 8931413
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group IV)
Trial: 3597990
Drug: d-sotalol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-sotalol (1, 1.5 or 2 mg/kg body weight)
Trial: 22858800
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NC)
Trial: 29132404
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg FP-1201-lyo administered intravenously once daily for 6 days
Trial: 29132404
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously once daily for 6 days
Trial: 29132404
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg FP-1201-lyo
Trial: 26314817
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 800 μg (400 μg/inhalation × 2 inhalations)
Trial: 26314817
Drug: Fp DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fp DPI 1000 μg (250 μg/inhalation × 4 inhalations)
Trial: 26314817
Drug: Fp MDI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDI 880 μg (220 μg/inhalation × 4 inhalations)
Trial: 8809957
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antibody prior to transfusions
Trial: 8809957
Drug: HLA-antibodies reacting
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-antibodies reacting with over 95% of unselected lymphocytes
Trial: 22986318
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) lidocaine
Trial: 20520820
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) immunization with inactivated influenza vaccine (TETAGRIP)
Trial: 20520820
Drug: Transcutaneous application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous application of inactivated influenza vaccine (TETAGRIP)
Trial: 12455077
Drug: Verapamil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (1 mg over 2 min) administered via an infusion catheter distal to the angioplasty site.
Trial: 8969027
Drug: Papaverine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine administered intraluminally, retrograde in the internal mammary artery
Trial: 8969027
Drug: Papaverine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine administered topically
Trial: 3885884
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg every 6 hours for one week)
Trial: 26949378
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein hydrolysate-carbohydrate beverage (PRO-CHO, 14 g protein/h and 69 g CHO/h)
Trial: 25557316
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2000 IU cholecalciferol daily)
Trial: 12973482
Drug: Gentamicin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin at a dose of 4 mg/kg every 24 hours (protocol group)
Trial: 12973482
Drug: Gentamicin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin at a dose of 2.5 mg/kg every 12 hours (control group)
Trial: 8717567
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 0.5 mg of Syntometrine
Trial: 1828508
Drug: Couple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple therapy (T) group, N = 33
Trial: 21389626
Drug: Casein hydrolysate
RxNorm normalized name: casein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein hydrolysate tablets (5 times more than the effective amount)
Trial: 19631773
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound treatment
Trial: 17920202
Drug: Topical antimicrobials
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobials
Trial: 14689459
Drug: Multisensory intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multisensory intervention (auditory, tactile, visual stimulation) for 15 min, twice a day, 5 days a week, for 4 weeks
Trial: 3240634
Drug: Nine-week program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine-week program of submaximal aerobic exercise three times weekly
Trial: 31621251
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (A)
Trial: 21512498
Drug: Neyromidin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neyromidin (15 mg intramuscularly 1 time a day for 10 days)
Trial: 21512498
Drug: Cerebrolysin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (10 ml intravenously 1 time a day for 10 days)
Trial: 12870569
Drug: Quetiapine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (600 mg/day)
Trial: 16162678
Drug: 13C‐UBT 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C‐UBT 25 mg
Trial: 16162678
Drug: 13C‐UBT 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C‐UBT 15 mg
Trial: 16162678
Drug: 13C‐UBT 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C‐UBT 10 mg
Trial: 16162678
Drug: 13C‐UBT 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C‐UBT 15 mg (post-treatment)
Trial: 12783624
Drug: Solution-focused follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused follow-up
Trial: 9355903
Drug: Bidisomide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidisomide 400 mg BID
Trial: 9355903
Drug: Bidisomide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidisomide 600 mg BID
Trial: 9355903
Drug: Bidisomide 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidisomide 200 mg BID
Trial: 8473088
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (cefoxitin)
Trial: 3318897
Drug: Felodipine 2.5
RxNorm normalized name: felodipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 2.5 mg twice daily
Trial: 2894980
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg twice daily
Trial: 2894980
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg twice daily
Trial: 2894980
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo twice daily
Trial: 29747611
Drug: Simulated surgical
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated surgical crown lengthening with 1.0 mm buccal ferrule (Group CL/F1)
Trial: 29747611
Drug: Simulated surgical
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated surgical crown lengthening with 2.0 mm buccal ferrule (Group CL/F2)
Trial: 20467146
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy device with defibrillator (CRT-D)
Trial: 8694041
Drug: Inhaled beclomethasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone, beta 2‐adrenergic receptor agonist, and an oral corticosteroid taper
Trial: 8694041
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline and inhaled beta 2‐adrenergic receptor agonist
Trial: 8694041
Drug: Beta 2‐adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2‐adrenergic receptor agonist and corticosteroid taper
Trial: 6338693
Drug: Sucrose polyester
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose polyester (SPE) 8 g/day
Trial: 6338693
Drug: Sucrose polyester
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose polyester (SPE) 16 g/day
Trial: 7543597
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of the AUA symptom index
Trial: 23579344
Drug: Fixed-combination brinzolamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination brinzolamide, 1%, and brimonidine, 0.2%
Trial: 20522466
Drug: Peer-mentoring by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-mentoring by a lay-worker fortnightly during pregnancy and monthly for the following year, tailored to participants' wishes (home visits/telephone contacts), additional to usual care.
Trial: 9160916
Drug: Cimetidine (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (local treatment for 4 weeks)
Trial: 8105773
Drug: Brimonidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine administered before the procedure
Trial: 8105773
Drug: Brimonidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine administered after the procedure
Trial: 8105773
Drug: Vehicle administered
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle administered before and after the procedure
Trial: 26774112
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (80 mL and 30 mL)
Trial: 14636909
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg twice daily for 6 weeks
Trial: 8623945
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 20 mL of propofol alone in a commercial preparation (Diprivan(R) with 10 mL of saline)
Trial: 8623945
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 20 mL of propofol and 10 mL of LCT fat emulsion
Trial: 8623945
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 20 mL of propofol with 5 mL of long‐chain triglyceride (LCT) fat emulsion and 5 mL of saline
Trial: 23106878
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) capsules, 120 - 160 mg daily for 6 months
Trial: 23106878
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) capsules
Trial: 18626271
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1.0 mg/kg) MDMA
Trial: 10220130
Drug: New antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antipsychotics
Trial: 31554388
Drug: 14-day high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics (37.5 mg Lactobacillus reuteri, Biogaia® in tablet twice daily)
Trial: 31554388
Drug: 7-day high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day high dose PPI-bismuth-containing quadruple therapy with probiotics
Trial: 31554388
Drug: 14-day high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics
Trial: 27858873
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Dexrazoxane (Chemo + DRZ)
Trial: 27858873
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Chemo)
Trial: 20507398
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week (eow)
Trial: 17365264
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg weekly
Trial: 20298496
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (adalimumab eow, adalimumab weekly, placebo)
Trial: 18205098
Drug: Aliskiren and
RxNorm normalized name: aliskiren and amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren and Ramipril combination
Trial: 2844981
Drug: Deferred maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred maintenance therapy after crossover
Trial: 31590179
Drug: Naltrexone (NTX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX; 50 mg/day) + placebo memantine
Trial: 31590179
Drug: Naltrexone (NTX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX; 50 mg/day) alone
Trial: 25440636
Drug: Respiratory rate
RxNorm normalized name: respiratory rate measuring device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory rate of 15 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Trial: 25440636
Drug: Respiratory rate
RxNorm normalized name: respiratory rate measuring device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory rate of 18 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Trial: 25440636
Drug: Respiratory rate
RxNorm normalized name: respiratory rate measuring device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory rate of 22 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Trial: 24377221
Drug: Intermittent wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent wave (IW) electroacupuncture combined with rehabilitation therapy
Trial: 24377221
Drug: Disperse-dense wave
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disperse-dense wave (DW) electroacupuncture combined with rehabilitation therapy
Trial: 24377221
Drug: Continuous wave
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wave (CW) electroacupuncture combined with rehabilitation therapy
Trial: 19012954
Drug: MRKAd5 HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRKAd5 HIV-1 gag/pol/nef vaccine
Trial: 7422170
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of ethinyl estradiol and levonorgestrel (Nordiol)
Trial: 30565715
Drug: CHx/alcohol‐combination (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHx/alcohol‐combination (1% CHx and 61% ethanol) applied with rub technique
Trial: 20297707
Drug: Conventional Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Restorative Treatment (CRT)
Trial: 27029801
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART)
Trial: 21524172
Drug: Ultra-Conservative Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-Conservative Treatment (UCT)
Trial: 10753002
Drug: Metrifonate 60/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 60/80 mg
Trial: 7863722
Drug: Chewable pyrantel
RxNorm normalized name: pyrantel Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable pyrantel pamoate tablets (pulverized)
Trial: 2644954
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and Radiation Therapy
Trial: 235144
Drug: Weekly psychotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly psychotherapy
Trial: 235144
Drug: Once monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once monthly psychotherapy
Trial: 10678268
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg prazosin
Trial: 21693504
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in systolic blood pressure (SBP) during treatment
Trial: 18274852
Drug: Finalized questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finalized questionnaire administered to patients
Trial: 15580194
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (1mg/m2/day)
Trial: 8273900
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (IVPCA) with 10 mg pethidine
Trial: 8273900
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (IVPCA) with 20 mg pethidine
Trial: 29294081
Drug: Daily Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Activities control condition
Trial: 18261537
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (E) 10 mg/d
Trial: 18261537
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (E(−):L(−))
Trial: 14608128
Drug: Bivalirudin high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin high-dose group (1 mg/kg bolus; 2.5 mg/kg/hour infusion for 4 hours)
Trial: 14608128
Drug: Bivalirudin low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bivalirudin low-dose group (0.75 mg/kg bolus; 1.75 mg/kg/hour infusion)
Trial: 14608128
Drug: Bivalirudin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (both high and low dose)
Trial: 8462363
Drug: High-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose octreotide (N = 9)
Trial: 21678169
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of implementation intentions and self-efficacy (II + SE)
Trial: 9666765
Drug: Single-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antibiotic prophylaxis with 1 g of ceftriaxone intravenously 1-2 hours before surgery
Trial: 7634503
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose r‐hGH (20 IU/m2/week)
Trial: 7634503
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose r‐hGH (40 IU/m2/week)
Trial: 7634503
Drug: r‐hGH therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐hGH therapy
Trial: 10895994
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (PT)
Trial: 25791116
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated recombinant tetravalent dengue vaccine candidate (TDV), given in 2 doses 90 days apart
Trial: 20971463
Drug: Conventional intracytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intracytoplasmic sperm injection (ICSI); n = 53 couples
Trial: 7674688
Drug: No anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulation or antiplatelet therapy
Trial: 22157392
Drug: Azithromycin ophthalmic
RxNorm normalized name: azithromycin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin ophthalmic solution 1% administered bid on days 1 and 2 and on days 3 to 29±1
Trial: 22157392
Drug: Visine for
RxNorm normalized name: Visine for Contacts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visine for Contacts rewetting drops administered qid on days 1 to 29±1
Trial: 20813346
Drug: Azithromycin ophthalmic
RxNorm normalized name: azithromycin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin ophthalmic solution 1%
Trial: 11175372
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of 4-aminopyridine at 5 microg/h for 4-5 hours